Report: Dendreon looking for buyer

Share this article:

Dendreon's continued slump appears to have forced its hand: Bloomberg reported Monday that the drugmaker, known for its prostate cancer med Provenge, has asked JPMorgan Chase to help it find a buyer.

Dendreon's financial forecasts have been dim: the company managed to narrow its losses during the second quarter, but said in August that it would not be able to hit its 2013 sales target, despite proof that potential patients were responding to its television ads.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.